In conclusion, our studies show that B7H6 is not only commonly expressed on established tumor cell lines of different origins but also on primary AML and melanoma samples, which further highlights the potential of the de novo expressed tumor-antigen B7H6 for CAR T therapy. The gene discussed is NCR3LG1; the disease is melanoma.